Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials.

Abstract

BACKGROUND:

Indacaterol is a novel, once-daily (od), inhaled, long-acting β(2)-agonist bronchodilator for maintenance treatment of airflow limitation in patients with COPD. The aim of this study was to evaluate the efficacy of indacaterol on dyspnea, using available randomized placebo-controlled trials.

METHODS:

A systematic search was made of MEDLINE, EMBASE, the Cochrane trials databases, and a manual search of journals. Randomized placebo-controlled trials of 12 weeks or more comparing indacaterol with placebo were reviewed, and eligible studies were included in a meta-analysis. The odds ratio (OR) for likelihood of achieving TDI score ≥ 1 after 12 weeks of treatment was used as an outcome measure to compare indacaterol to placebo.

RESULTS:

Six trials were included in the analysis. Relative to placebo, the overall ORs for response were: indacaterol 75 μg od 1.784 (95% CI 1.282 to 2.482); indacaterol 150 μg od 2.149 (95% CI 1.746 to 2.645); and indacaterol 300 μg od 2.458 (95% CI 2.010 to 3.006). Overall OR for response in TDI tended to increase with higher indacaterol doses.

CONCLUSIONS:

Patients receiving indacaterol had clinically significant improvements in symptoms of dyspnea compared to placebo. Incremental benefits in TDI were observed with increasing doses. Indacaterol may provide patients and physicians with a useful treatment option in symptomatic patients with dyspnea.

• Authors: Jiangna Han, Lu Dai, Nanshan Zhong
• Journal: BMC pulmonary medicine (BMC Pulm Med) Vol. 13 Pg. 26 (Apr 25 2013) ISSN: 1471-2466 [Electronic] England
• PMID: 23617268 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review, Systematic Review)

Chemical References

• Adrenergic beta-2 Receptor Agonists
• Indans
• Placebos
• Quinolones
• indacaterol

Topics

• Adrenergic beta-2 Receptor Agonists (therapeutic use)
• Dyspnea (drug therapy, mortality)
• Humans
• Indans (therapeutic use)
• Placebos
• Pulmonary Disease, Chronic Obstructive (drug therapy, mortality)
• Quinolones (therapeutic use)
• Randomized Controlled Trials as Topic